Evidence map›Paper›PMID 35859615›Full record

ArticleOpen life sciences2022

MT-12 inhibits the proliferation of bladder cells

Yan Chen, Chengxing Xia, Chunwei Ye, Feineng Liu, Yitian Ou, Ruping Yan, Haifeng Wang, Delin Yang

Open access · goldAbstract read
In one paragraph

Article in Open life sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

Yan ChenDepartment of Urology, The Second Affiliated Hospital of Kunming Medical University, 374 Burma Avenue, Kunming 650101, China.
Chengxing XiaDepartment of Urology, The Second Affiliated Hospital of Kunming Medical University, 374 Burma Avenue, Kunming 650101, China.
Chunwei YeDepartment of Urology, The Second Affiliated Hospital of Kunming Medical University, 374 Burma Avenue, Kunming 650101, China.
Feineng LiuDepartment of Urology, The Second Affiliated Hospital of Kunming Medical University, 374 Burma Avenue, Kunming 650101, China.
Yitian OuDepartment of Urology, The Second Affiliated Hospital of Kunming Medical University, 374 Burma Avenue, Kunming 650101, China.
Ruping YanDepartment of Urology, The Second Affiliated Hospital of Kunming Medical University, 374 Burma Avenue, Kunming 650101, China.
Haifeng WangDepartment of Urology, The Second Affiliated Hospital of Kunming Medical University, 374 Burma Avenue, Kunming 650101, China.
Delin YangDepartment of Urology, The Second Affiliated Hospital of Kunming Medical University, 374 Burma Avenue, Kunming 650101, China.
Kunming Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Bladder cancer (BC) is one of the most common malignancies involving the urinary system. Our previous study demonstrated that cobra venom membrane toxin 12 (MT-12) could effectively inhibit BC cell growth and metastasis and induce apoptosis. However, the specific molecular mechanism remains unknown. In this study, we explored whether MT-12 inhibits BC cell proliferation by inducing autophagy cell death through mitochondrial dysfunction. As a result, MT-12 inhibited proliferation and colony formation in RT4 and T24 cells. In the BC xenograft mouse model, autophagy inhibitor 3-MA alleviated the inhibitory effect of MT-12 on tumor growth. In addition, immunostaining revealed downregulated autophagy in MT-12-treated RT4 and T24 cells. We also found that MT-12 led to dysfunctional mitochondria with decreased mitochondrial membrane potential, mtDNA abundance, and increased ROS production, ultimately inducing autophagic apoptosis

Indexed as

autophagybladder cancerCobra venom membrane toxin 12mitochondrial dysfunctionROS

Identifiers

PMID35859615
PMCPMC9267309
OpenAlexW4285137749

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.